Alzheimer’s disease diagnosis and classification using deep learning
The Dementia Consortium
Stem cells reveal new insights into the biology of Alzheimer’s disease
New biological research framework for Alzheimer's seeks to spur discovery
Alzheimer’s Disease: Some trials to watch over the next year
Frontiers
COMMENTS
What's Next for Alzheimer's Disease Treatments: A 2024 Forecast
Two Phase 3 clinical trials for the upcoming Alzheimer's drug, simufilam, are expected to end this year. The REFOCUS trial is investigating two different doses of simufilam (50mg or 100mg) in people with mild to moderate Alzheimer's over 76 weeks and is expected to end in July. The other trial, called RETHINK, examines a 100mg dose of the ...
Current and Future Treatments in Alzheimer Disease: An Update
Introduction. Alzheimer disease (AD) is one of the greatest medical care challenges of our century and is the main cause of dementia. In total, 40 million people are estimated to suffer from dementia throughout the world, and this number is supposed to become twice as much every 20 years, until approximately 2050. 1 Because dementia occurs mostly in people older than 60 years, the growing ...
NIH Awards $6.9 Million to Advance Potential Alzheimer's Disease Treatment
Article Content. A multidisciplinary team of scientists led by Carlo Ballatore, Ph.D., at University of California San Diego and Kurt Brunden, Ph.D., at the University of Pennsylvania has been awarded a $6.9 million grant from the National Institute on Aging (NIA) to prepare a potential disease-modifying Alzheimer's treatment for future clinical trials.
Recent advances in Alzheimer's disease: Mechanisms, clinical ...
Dementia has emerged as a global health challenge. According to the World Health Organization's 2022 blueprint for dementia research, an estimated 55.2 million individuals globally are affected.
Emerging diagnostics and therapeutics for Alzheimer disease
Abstract. Alzheimer disease (AD) is the most common contributor to dementia in the world, but strategies that slow or prevent its clinical progression have largely remained elusive, until recently ...
NIH releases 2022 dementia research progress report
November 8, 2022. Alzheimer's Disease. NIH has released Advancing Alzheimer's Disease and Related Dementias Research for All Populations: Prevent. Diagnose. Treat. Care. (PDF, 17M), a 2022 scientific progress report. The report features science advances and related efforts made between March 2021 and early 2022 in areas including drug ...
Conquering Alzheimer's: a look at the therapies of the future
What thrilled Sperling, who won the award for her work on clinical trials of Alzheimer's treatments, was a sense of hope, which has been conspicuously missing from research into the disease for ...
Start of new era for Alzheimer's treatment
Researchers say we appear to be at the start of a new era for Alzheimer's treatment. Trial results published in January showed that for the first time a drug has been able to slow the cognitive decline characteristic of the disease. The drug, lecanemab, is a monoclonal antibody that works by binding to a key protein linked to the malady ...
UC Irvine Researchers Unveil Promising New Treatment Approach for
Professor Tenner highlighted the importance of these results for future clinical applications: "Importantly, all these beneficial effects were seen with adult administration of the drug after the onset of plaque deposition in mouse models, which mimics the time at which patients begin to exhibit signs of Alzheimer's disease. As a result ...
Progress with Treatments for Alzheimer's Disease
Abstract. An estimated 50 million people worldwide have dementia, mostly due to Alzheimer's disease. The inexorable progression of Alzheimer's disease exerts a huge toll on patients, families ...
Future Alzheimer's Treatments Look Beyond Amyloid For Ways To ...
Future Alzheimer's Treatments Look Beyond Amyloid For Ways To Protect The Brain : ... co-director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida.
Current Alzheimer disease research highlights: evidence for novel risk
In this section, we will review and summarize the recent progress in the research of AD focusing on five novel potential risk factors or early disease indicators such as sleep, hypoxia, diet, gut microbiota, and hearing impairment. As these factors are relatively novel, this review focuses on the epidemiologic evidence with some discussion of ...
Cancer drug could treat early-stage Alzheimer
In 2023, as many as 6.7 million Americans were living with Alzheimer's disease, according to the Centers for Disease Control and Prevention, and its prevalence is expected to triple by 2060.
Alzheimer's treatments: What's on the horizon?
This has led to the research of potential Alzheimer's treatments that may affect the disease process. Future Alzheimer's treatments may include a combination of medicines. ... the 1990s suggested that taking hormone replacement therapy during perimenopause and menopause lowered the risk of Alzheimer's disease. But further research has been ...
Recent breakthroughs in Alzheimer's research provide hope for ...
Jan. 24, 2023. Lori Weiss, 65, a retired teacher, has early onset Alzheimer's disease. She is enrolled in a drug clinical trial and is hopeful about recent progress in disease research. Courtesy of Lori Weiss. A few years ago, Lori Weiss, a high school math and engineering teacher, noticed it was taking her longer to do her lesson plans and ...
Multiple sclerosis appears to protect against Alzheimer's disease
The discovery suggests a new avenue of research through which to seek Alzheimer's treatments, said Matthew Brier, MD PhD, an assistant professor of neurology and of radiology and the study's first ...
New blood test to identify Alzheimer's Disease could change how the
Research just published in the leading international journal Alzheimer's Research & Therapy outlines a study undertaken in the Institute of Memory & Cognition at Tallaght University ... blood tests such as plasma p-tau217 demonstrate excellent performance to detect the changes that are characteristic of Alzheimer's disease. In the future ...
Alzheimer's disease: 120 years of research and progress
treatment of alzheimer's disease: current available medications and future research Alzheimer's disease currently has a few classes of medication available for treatment. Cholinesterase inhibitors, such as Donepezil, Rivastigmine, and Galantamine, are the first possible treatment plan for patients with Alzheimer's disease.
New compound shows promise in Alzheimer's preclinical models
A multidisciplinary team of scientists led by Kurt Brunden, Ph.D., at the University of Pennsylvania Perelman School of Medicine, and Carlo Ballatore, Ph.D., at University of California San Diego ...
Alzheimer's drug may someday help save lives by inducing a state of
New research in tadpoles reveals that FDA-approved donepezil puts the animals in reversible torpor-like state . By Lindsay Brownell. Tadpoles from the Xenopus laevis species of frogs are good models for human neurology, because they are easy to grow in large numbers and changes in their behavior are easy to see and record. Credit: Unravel Biosciences
Prospects for Future Advances in Alzheimer's Disease
This paper revisits expert predictions for future advances in Alzheimer's disease (AD) made in 2001 and projects future breakthroughs over the next 20 years. ... The need for a breakthrough in AD research is clear. When the U.S. Food and Drug Administration approved tacrine (Cognex®) in the early 1990s, the status quo of AD treatment was one ...
Simple blood test for Alzheimer's disease could change how the disease
Patients who are undergoing a diagnostic lumbar puncture for the detection of Alzheimer's disease at TUH opt to donate cerebrospinal fluid and blood samples for future research. This is crucial in ...
The future of Alzheimer's disease: the next 10 years
Based on the meeting of the German Task Force on Alzheimer's Disease (GTF-AD) in Paris on July 19th 2011, the present position paper provides an overview on the current state and future developments in epidemiology, pathophysiology, disease conceptualization, diagnostic criteria and their use in research and clinical practice, as well as ...
Researchers call for a major rethink of how Alzheimer's ...
In studies of potential disease-modifying drugs for Alzheimer's disease, there has always been a tension between being able to produce a treatment effect and being able to measure it, says ...
Rationale and design of the BeyeOMARKER study: prospective evaluation
The hallmark pathophysiological processes of Alzheimer's disease (AD; i.e., amyloid β [Aβ] plaques and neurofibrillary tau tangles) may emerge 20-30 years prior to the onset of dementia, and the earliest incipient symptoms often go unnoticed by patients and their caregivers [1,2,3].Early AD, prior to extensive atrophy and cognitive impairment, is the optimal window for intervention and ...
Alzheimer's Disease: Past, Present, and Future
Alzheimer published his now famous case study only 110 years ago, and our modern understanding of the disease that bears his name, and its neuropsychological consequences, really only began to accelerate in the 1980s. Since then we have witnessed an explosion of basic and translational research into the causes, characterizations, and possible ...
Do we have Alzheimer's disease all wrong?
As Science noted last week, the Alzheimer's study is among the most cited papers ever to be retracted after accumulating nearly 2,500 citations over the past 18 years. The 2006 paper had ...
Multiple sclerosis appears to protect against Alzheimer's disease
The discovery suggests a new avenue of research through which to seek Alzheimer's treatments, said Matthew Brier, MD PhD, an assistant professor of neurology and radiology and the study's first author. ... "Perhaps when the Alzheimer's disease amyloid pathology was developing, the patients with MS had some degree of inflammation in ...
Rationale and design of the BeyeOMARKER study: prospective ...
Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer's disease pathology in the eye clinic Alzheimers Res Ther . 2024 Aug 21;16(1):190. doi: 10.1186/s13195-024-01545-1.
Drug That Induces Labor Shows Promise as Alzheimer's Treatment
A drug used to induce labor has the potential to protect the aging brain from a build-up of toxic waste implicated in neurodegenerative conditions like Alzheimer's disease. In small doses, the hormone-mimicking compound prostaglandin F2α can be used to induce smooth muscle contractions in the womb to encourage delivery or help reduce blood ...
IMAGES
COMMENTS
Two Phase 3 clinical trials for the upcoming Alzheimer's drug, simufilam, are expected to end this year. The REFOCUS trial is investigating two different doses of simufilam (50mg or 100mg) in people with mild to moderate Alzheimer's over 76 weeks and is expected to end in July. The other trial, called RETHINK, examines a 100mg dose of the ...
Introduction. Alzheimer disease (AD) is one of the greatest medical care challenges of our century and is the main cause of dementia. In total, 40 million people are estimated to suffer from dementia throughout the world, and this number is supposed to become twice as much every 20 years, until approximately 2050. 1 Because dementia occurs mostly in people older than 60 years, the growing ...
Article Content. A multidisciplinary team of scientists led by Carlo Ballatore, Ph.D., at University of California San Diego and Kurt Brunden, Ph.D., at the University of Pennsylvania has been awarded a $6.9 million grant from the National Institute on Aging (NIA) to prepare a potential disease-modifying Alzheimer's treatment for future clinical trials.
Dementia has emerged as a global health challenge. According to the World Health Organization's 2022 blueprint for dementia research, an estimated 55.2 million individuals globally are affected.
Abstract. Alzheimer disease (AD) is the most common contributor to dementia in the world, but strategies that slow or prevent its clinical progression have largely remained elusive, until recently ...
November 8, 2022. Alzheimer's Disease. NIH has released Advancing Alzheimer's Disease and Related Dementias Research for All Populations: Prevent. Diagnose. Treat. Care. (PDF, 17M), a 2022 scientific progress report. The report features science advances and related efforts made between March 2021 and early 2022 in areas including drug ...
What thrilled Sperling, who won the award for her work on clinical trials of Alzheimer's treatments, was a sense of hope, which has been conspicuously missing from research into the disease for ...
Researchers say we appear to be at the start of a new era for Alzheimer's treatment. Trial results published in January showed that for the first time a drug has been able to slow the cognitive decline characteristic of the disease. The drug, lecanemab, is a monoclonal antibody that works by binding to a key protein linked to the malady ...
Professor Tenner highlighted the importance of these results for future clinical applications: "Importantly, all these beneficial effects were seen with adult administration of the drug after the onset of plaque deposition in mouse models, which mimics the time at which patients begin to exhibit signs of Alzheimer's disease. As a result ...
Abstract. An estimated 50 million people worldwide have dementia, mostly due to Alzheimer's disease. The inexorable progression of Alzheimer's disease exerts a huge toll on patients, families ...
Future Alzheimer's Treatments Look Beyond Amyloid For Ways To Protect The Brain : ... co-director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida.
In this section, we will review and summarize the recent progress in the research of AD focusing on five novel potential risk factors or early disease indicators such as sleep, hypoxia, diet, gut microbiota, and hearing impairment. As these factors are relatively novel, this review focuses on the epidemiologic evidence with some discussion of ...
In 2023, as many as 6.7 million Americans were living with Alzheimer's disease, according to the Centers for Disease Control and Prevention, and its prevalence is expected to triple by 2060.
This has led to the research of potential Alzheimer's treatments that may affect the disease process. Future Alzheimer's treatments may include a combination of medicines. ... the 1990s suggested that taking hormone replacement therapy during perimenopause and menopause lowered the risk of Alzheimer's disease. But further research has been ...
Jan. 24, 2023. Lori Weiss, 65, a retired teacher, has early onset Alzheimer's disease. She is enrolled in a drug clinical trial and is hopeful about recent progress in disease research. Courtesy of Lori Weiss. A few years ago, Lori Weiss, a high school math and engineering teacher, noticed it was taking her longer to do her lesson plans and ...
The discovery suggests a new avenue of research through which to seek Alzheimer's treatments, said Matthew Brier, MD PhD, an assistant professor of neurology and of radiology and the study's first ...
Research just published in the leading international journal Alzheimer's Research & Therapy outlines a study undertaken in the Institute of Memory & Cognition at Tallaght University ... blood tests such as plasma p-tau217 demonstrate excellent performance to detect the changes that are characteristic of Alzheimer's disease. In the future ...
treatment of alzheimer's disease: current available medications and future research Alzheimer's disease currently has a few classes of medication available for treatment. Cholinesterase inhibitors, such as Donepezil, Rivastigmine, and Galantamine, are the first possible treatment plan for patients with Alzheimer's disease.
A multidisciplinary team of scientists led by Kurt Brunden, Ph.D., at the University of Pennsylvania Perelman School of Medicine, and Carlo Ballatore, Ph.D., at University of California San Diego ...
New research in tadpoles reveals that FDA-approved donepezil puts the animals in reversible torpor-like state . By Lindsay Brownell. Tadpoles from the Xenopus laevis species of frogs are good models for human neurology, because they are easy to grow in large numbers and changes in their behavior are easy to see and record. Credit: Unravel Biosciences
This paper revisits expert predictions for future advances in Alzheimer's disease (AD) made in 2001 and projects future breakthroughs over the next 20 years. ... The need for a breakthrough in AD research is clear. When the U.S. Food and Drug Administration approved tacrine (Cognex®) in the early 1990s, the status quo of AD treatment was one ...
Patients who are undergoing a diagnostic lumbar puncture for the detection of Alzheimer's disease at TUH opt to donate cerebrospinal fluid and blood samples for future research. This is crucial in ...
Based on the meeting of the German Task Force on Alzheimer's Disease (GTF-AD) in Paris on July 19th 2011, the present position paper provides an overview on the current state and future developments in epidemiology, pathophysiology, disease conceptualization, diagnostic criteria and their use in research and clinical practice, as well as ...
In studies of potential disease-modifying drugs for Alzheimer's disease, there has always been a tension between being able to produce a treatment effect and being able to measure it, says ...
The hallmark pathophysiological processes of Alzheimer's disease (AD; i.e., amyloid β [Aβ] plaques and neurofibrillary tau tangles) may emerge 20-30 years prior to the onset of dementia, and the earliest incipient symptoms often go unnoticed by patients and their caregivers [1,2,3].Early AD, prior to extensive atrophy and cognitive impairment, is the optimal window for intervention and ...
Alzheimer published his now famous case study only 110 years ago, and our modern understanding of the disease that bears his name, and its neuropsychological consequences, really only began to accelerate in the 1980s. Since then we have witnessed an explosion of basic and translational research into the causes, characterizations, and possible ...
As Science noted last week, the Alzheimer's study is among the most cited papers ever to be retracted after accumulating nearly 2,500 citations over the past 18 years. The 2006 paper had ...
The discovery suggests a new avenue of research through which to seek Alzheimer's treatments, said Matthew Brier, MD PhD, an assistant professor of neurology and radiology and the study's first author. ... "Perhaps when the Alzheimer's disease amyloid pathology was developing, the patients with MS had some degree of inflammation in ...
Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer's disease pathology in the eye clinic Alzheimers Res Ther . 2024 Aug 21;16(1):190. doi: 10.1186/s13195-024-01545-1.
A drug used to induce labor has the potential to protect the aging brain from a build-up of toxic waste implicated in neurodegenerative conditions like Alzheimer's disease. In small doses, the hormone-mimicking compound prostaglandin F2α can be used to induce smooth muscle contractions in the womb to encourage delivery or help reduce blood ...